EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)

An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B Cohen, Craig A Portell, Mehdi Hamadani, Opeyemi Jegede, Catherine Diefenbach, Christopher Fletcher, Matthew Matasar, Daniel Landsburg, Suparna Mantha, Brad Kahl

Clinical Lymphoma Myeloma and Leukemia · 2026-07 · 26 (7) · 465-473.e1

DOI: 10.1016/j.clml.2026.04.025 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-07. Verfasst von Jonathon B Cohen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA. Electronic address: Jonathon.cohen@emory.edu. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Piperidines, Adenine, Glycine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Management of relapsed mantle cell lymphoma (MCL) has included Bruton's tyrosine kinase (BTK) inhibitors for more than 10 years, but finding an optimal combination partner that meaningfully improves outcomes while limiting toxicity has been difficult. We conducted a phase 1/2 trial of ibrutinib and the proteasome inhibitor, ixazomib, in patients with relapsed/refractory MCL. PATIENTS AND METHODS Patients and Methods: The primary endpoint for the phase 1 study was to determine the recommended phase 2 dose (RP2D), and for the phase 2 study was the complete response (CR) rate, compared with the previously reported single-agent CR rate of ibrutinib. After the phase 1 portion of the study identified a recommended phase 2 dose of ixazomib 4 mg days 1, 8, and 15, of a 28-day cycle combined with ibrutinib 560 mg daily until progression or unacceptable toxicity. RESULTS We enrolled 35 BTK-naïve patients to the phase 2 portion of the study. Overall response rate was 77%, and 37% of patients achieved a CR. The 2-year progression-free survival is 44%, and the duration of response is 47%. Treatment-related adverse events were common, resulting in treatment discontinuation for 37% of patients. CONCLUSION Given that the progression-free survival (PFS) was not significantly improved compared to historical reports for single-agent BTK inhibitors and the high rate of treatment-related toxicity, this combination does not merit further study in this setting. Additional trials evaluating newer BTK inhibitors and alternative combination partners are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellPiperidinesAdenineGlycineBoron CompoundsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalHumansFemaleMaleAgedMiddle AgedAged, 80 and overPyrimidinesPyrazolesAdult

Stichwörter der Autor:innen

BTK inhibitorsClinical trialNon-Hodgkin lymphomaProteasome inhibitorsTargeted therapy

Substanzen

PiperidinesibrutinibAdenineixazomibGlycineBoron CompoundsPyrimidinesPyrazoles

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Emory University Winship Cancer Institute, Atlanta, GA. Electronic address: Jonathon.cohen@emory.edu.
  • Department of Medicine, Division of Hematology/Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA.
  • Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
  • Biostatistics Center for ECOG/ACRIN, Dana Farber Cancer Institute, Boston, MA.
  • Department of Medicine, Perlmutter Cancer Center at NYU Langone Health, New York, NY.
  • Department of Medicine, University of Wisconsin, Madison, WI.

Zitieren

APA

Cohen, J. B., Portell, C. A., Hamadani, M., Jegede, O., Diefenbach, C., Fletcher, C., Matasar, M., Landsburg, D., Mantha, S., & Kahl, B. (2026). An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. Clinical Lymphoma Myeloma and Leukemia, 26(7), 465-473.e1. https://doi.org/10.1016/j.clml.2026.04.025

Vancouver

Cohen JB, Portell CA, Hamadani M, Jegede O, Diefenbach C, Fletcher C, et al. An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. Clinical Lymphoma Myeloma and Leukemia. 2026;26(7):465-473.e1. doi:10.1016/j.clml.2026.04.025

BibTeX
@article{Cohen2026,
  author = {Cohen, Jonathon B and Portell, Craig A and Hamadani, Mehdi and Jegede, Opeyemi and Diefenbach, Catherine and Fletcher, Christopher and Matasar, Matthew and Landsburg, Daniel and Mantha, Suparna and Kahl, Brad},
  title = {An Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  volume = {26},
  number = {7},
  pages = {465--473.e1},
  doi = {10.1016/j.clml.2026.04.025}
}
Kostenlos starten →